Wednesday, June 10, 2026

pharma Β· Prostate Cancer Β· Hot Flush

Astellas Pharma

Astellas Pharma clinical programs β€” 9 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, JP HQ
12,378 Employees
EMA registrant Type
Company details
Status
Public
HQ
2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, JP
Employees
12,378
Programs
22
Drugs
52
Patents
25
Intelligence Β· Clinical Programs

Astellas Pharma projects

9 ClinicalTrials.gov programs sponsored by Astellas Pharma.

Astellas Pharma has 9 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. 2215-CL-0201

    Astellas Pharma GmbH

    Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

    phase 3 small molecule active

    1 trial
  2. 2693-CL-1303

    Astellas Pharma GmbH

    Moderate to Severe Vasomotor Symptoms (VMS)

    phase 3 small molecule active

    1 trial
  3. 7465-CL-0301

    Astellas Pharma GmbH

    Locally advanced or metastatic urothelial cancer

    phase 3 small molecule active

    1 trial
  4. 8951-CL-0301

    Astellas Pharma GmbH

    Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

    phase 3 small molecule active

    1 trial
  5. 8951-CL-0302

    Astellas Pharma GmbH

    Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

    phase 3 small molecule active

    1 trial
  6. 8951-CL-0305

    Astellas Pharma GmbH

    Gastroesophageal Junction Adenocarcinoma, Gastric Cancer, Gastric Adenocarcinoma

    phase 3 small molecule active

    1 trial
  7. AT132

    Astellas Pharma GmbH

    X-linked Myotubular Myopathy (XLMTM)

    phase 3 small molecule active

    1 trial
  8. Avacincaptad pegol, FLUORESCEIN

    Astellas Pharma GmbH

    geographic atrophy

    phase 3 small molecule active

    1 trial
  9. Mirabegron

    Astellas Pharma GmbH

    Neurogenic detrusor overactivity (NDO)

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Astellas Pharma have?

9 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.